{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:46:56Z","timestamp":1793710016979,"version":"4.6.1"},"reference-count":368,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003156","name":"Musella Foundation For Brain Tumor Research &amp; Information Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.pharmr.2026.100138","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:58:51Z","timestamp":1778284731000},"page":"100138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reharnessing the therapeutic potential of gallium-based compounds in oncology: From the laboratory to the clinic"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-8218","authenticated-orcid":false,"given":"Christopher R.","family":"Chitambar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7252-5573","authenticated-orcid":false,"given":"Casey J.","family":"Zoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-4025","authenticated-orcid":false,"given":"Mona M.","family":"Al-Gizawiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Schmainda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-8573","authenticated-orcid":false,"given":"Jennifer M.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmr.2026.100138_bib1","series-title":"Advances in Inorganic Chemistry and Radiochemistry","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0065-2792(08)60153-3","article-title":"The chemistry of gallium","author":"Greenwood","year":"1963"},{"issue":"460","key":"10.1016\/j.pharmr.2026.100138_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7520","article-title":"Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections","volume":"10","author":"Goss","year":"2018","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10534-022-00406-4","article-title":"Evolution of gallium applications in medicine and microbiology: a timeline","volume":"35","author":"de Assis","year":"2022","journal-title":"Biometals"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10482-024-02015-2","article-title":"Gallium: a decisive \u201cTrojan horse\u201d against microorganisms","volume":"118","author":"de Assis","year":"2024","journal-title":"Antonie Leeuwenhoek"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0031-6997(24)01383-8","article-title":"Mechanisms of therapeutic activity for gallium","volume":"50","author":"Bernstein","year":"1998","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5012\/bkcs.2008.29.2.372","article-title":"Gallium(III) ion hydrolysis under physiological conditions","volume":"29","author":"Hacht","year":"2008","journal-title":"Bull Korean Chem Soc"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib7","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/ja01215a600","article-title":"Nuclei formed in fission: decay characteristics, fission yields, and chain relationships. (issued by the Plutonium Project)","volume":"68","year":"1946","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-3565(25)03505-0","article-title":"Studies of the metabolism of gallium","volume":"98","author":"Dudley","year":"1950","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0022-3565(25)03675-4","article-title":"Studies of the toxic action of gallium","volume":"95","author":"Dudley","year":"1949","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0001-2998(78)80027-0","article-title":"The medical use of gallium radionuclides: a brief history with some comments","volume":"8","author":"Hayes","year":"1978","journal-title":"Semin Nucl Med"},{"issue":"3916","key":"10.1016\/j.pharmr.2026.100138_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1126\/science.167.3916.289","article-title":"Gallium-67 localization in rat and mouse tumors","volume":"167","author":"Hayes","year":"1970","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0047-0740(83)90083-9","article-title":"Tissue distribution of [67Ga]citrate and 111InC13 in mouse with adenocarcinoma","volume":"10","author":"Saha","year":"1983","journal-title":"Int J Nucl Med Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0047-0740(81)90031-0","article-title":"The role of transferrins in gallium uptake","volume":"8","author":"Larson","year":"1981","journal-title":"Int J Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib14","first-page":"92","article-title":"Distribution of gallium in human tissues after intravenous administration","volume":"13","author":"Nelson","year":"1972","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0002-9343(76)90719-1","article-title":"Clinical usefulness of 67gallium scanning in the malignant lymphomas","volume":"60","author":"McCaffrey","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmr.2026.100138_bib16","first-page":"394","article-title":"Status of gallium-67 in tumor detection","volume":"21","author":"Hoffer","year":"1980","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00000658-198307000-00020","article-title":"Tomographic gallium-67 citrate scanning useful new surveillance for metastatic melanoma","volume":"198","author":"Kirkwood","year":"1983","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib18","first-page":"2101","article-title":"Early detection of lymphoma recurrence with gallium-67 scintigraphy","volume":"34","author":"Front","year":"1993","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/00006231-200010000-00006","article-title":"Correlation of flow cytometric parameters and transferrin receptors with gallium-67 scintigraphic images in lymphoma patients","volume":"21","author":"Kiratli","year":"2000","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib20","first-page":"40","article-title":"Ga. 67 scintigraphy in B-cell non-Hodgkin\u2019s lymphoma: correlation of Ga-67 uptake with histology and transferrin receptor expression","volume":"40","author":"Nejmeddine","year":"1999","journal-title":"J Nucl Med"},{"issue":"8323","key":"10.1016\/j.pharmr.2026.100138_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(83)92191-8","article-title":"Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma","volume":"321","author":"Habeshaw","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ijc.2910330204","article-title":"Transferrin receptor and B-lymphoblast antigen\u2014their relationship to DNA synthesis, histology and survival in B-cell lymphomas","volume":"33","author":"Kval\u00f8y","year":"1984","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0001-2998(05)80007-8","article-title":"The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients","volume":"25","author":"Front","year":"1995","journal-title":"Semin Nucl Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib24","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2007-06-097238","article-title":"The role of FDG-PET scans in patients with lymphoma","volume":"110","author":"Seam","year":"2007","journal-title":"Blood"},{"issue":"6B","key":"10.1016\/j.pharmr.2026.100138_bib25","first-page":"4087","article-title":"Gallium-68 PET: a new frontier in receptor cancer imaging","volume":"27","author":"Al-Nahhas","year":"2007","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100138_bib26","first-page":"1053","article-title":"PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas","volume":"42","author":"Henze","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharmr.2026.100138_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117760","article-title":"Approaching gallium-68 radiopharmaceuticals for tumor diagnosis: a Medicinal Chemist\u2019s perspective","volume":"294","author":"Musumeci","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2967\/jnumed.115.163865","article-title":"Safety and efficacy of 68 Ga-DOTATATE PET\/CT for diagnosis, staging, and treatment management of neuroendocrine tumors","volume":"57","author":"Deppen","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00259-025-07493-8","article-title":"Synthesis and preclinical evaluation of a 68Ga-labeled peptide for PET imaging of transferrin receptor 1 in tumor","volume":"53","author":"Lin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.pharmr.2026.100138_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbae015","article-title":"A transferrin receptor targeting dual-modal MR\/NIR fluorescent imaging probe for glioblastoma diagnosis","volume":"11","author":"Hao","year":"2024","journal-title":"Regen Biomater"},{"key":"10.1016\/j.pharmr.2026.100138_bib32","first-page":"650","article-title":"Radiogallium localization in tumors: blood binding and transport and the role of transferrin","volume":"21","author":"Vallabhajosula","year":"1980","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0047-0740(81)90033-4","article-title":"Comparative pharmacokinetics of 67Ga and 59Fe in humans","volume":"8","author":"Logan","year":"1981","journal-title":"Int J Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0001-2998(75)80004-3","article-title":"Studies of the erythron","volume":"5","author":"Pollycove","year":"1975","journal-title":"Semin Nucl Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1021\/bi00271a010","article-title":"Thermodynamic binding constants for gallium transferrin","volume":"22","author":"Harris","year":"1983","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0014-5793(98)00034-9","article-title":"[1 H, 13 C] NMR determination of the order of lobe loading of human transferrin with iron: comparison with other metal ions","volume":"422","author":"Sun","year":"1998","journal-title":"FEBS Lett"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib37","first-page":"837","article-title":"A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. I. Studies in tissue culture","volume":"20","author":"Larson","year":"1979","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharmr.2026.100138_bib38","first-page":"3634","article-title":"Transferrin promotion of 67Ga and 59Fe uptake by cultured mouse myeloma cells","volume":"37","author":"Harris","year":"1977","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100138_bib39","first-page":"1213","article-title":"67Ga and 59Fe uptake by cultured human lymphoblasts and lymphocytes","volume":"38","author":"Sephton","year":"1978","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100138_bib40","first-page":"41","article-title":"Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor","volume":"64","author":"Larson","year":"1980","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100138_bib41","doi-asserted-by":"crossref","first-page":"9943","DOI":"10.1016\/S0021-9258(19)86649-8","article-title":"Isolation and characterization of the transferrin receptor from human placenta","volume":"254","author":"Seligman","year":"1979","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib42","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1073\/pnas.79.4.1175","article-title":"Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro","volume":"79","author":"Trowbridge","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100138_bib43","first-page":"3929","article-title":"Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms","volume":"47","author":"Chitambar","year":"1987","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib44","first-page":"1215","article-title":"Mechanism involved in gallium-67 (Ga-67) uptake by human lymphoid cell lines","volume":"44","author":"Nejmeddine","year":"1998","journal-title":"Cell Mol Biol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib45","first-page":"1405","article-title":"Uptake of gallium-67 in transfected cells and tumors absent or enriched in the transferrin receptor","volume":"39","author":"Luttropp","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharmr.2026.100138_bib46","first-page":"1303","article-title":"Inhibition of gallium-67 uptake in melanoma by an anti-human transferrin receptor monoclonal antibody","volume":"28","author":"Chan","year":"1987","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00006231-200401000-00007","article-title":"Hypoxia as a factor for 67Ga accumulation in tumour cells","volume":"25","author":"Kinuya","year":"2004","journal-title":"Nucl Med Commun"},{"issue":"34","key":"10.1016\/j.pharmr.2026.100138_bib48","doi-asserted-by":"crossref","first-page":"24142","DOI":"10.1074\/jbc.274.34.24142","article-title":"Transferrin receptor induction by hypoxia","volume":"274","author":"Tacchini","year":"1999","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100138_bib49","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.cgh.2024.10.041","article-title":"Diagnosis and treatment of hemochromatosis","volume":"23","author":"Adams","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100138_bib50","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1074\/jbc.274.13.9022","article-title":"The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells","volume":"274","author":"Roy","year":"1999","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100138_bib51","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1182\/blood.V96.13.4020","article-title":"Iron homeostasis: new tales from the crypt","volume":"96","author":"Roy","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib52","first-page":"943","article-title":"Expression of the hemochromatosis (HFE) gene modulates the cellular uptake of 67Ga","volume":"44","author":"Chitambar","year":"2003","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib53","first-page":"R-67453","article-title":"Ascorbate preferentially stimulates gallium-67 uptake in glioblastoma cells","volume":"13","author":"Petronek","year":"2022","journal-title":"J Nucl Med Radiat Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jcp.1041280217","article-title":"Comparative studies of the binding and growth-supportive ability of mammalian transferrins in human cells","volume":"128","author":"Penhallow","year":"1986","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib55","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.bbamcr.2015.01.021","article-title":"Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease","volume":"1853","author":"Lane","year":"2015","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib56","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.bbamcr.2016.09.008","article-title":"Erythroid cell mitochondria receive endosomal iron by a \u201ckiss-and-run\u201d mechanism","volume":"1863","author":"Hamdi","year":"2016","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"5880","key":"10.1016\/j.pharmr.2026.100138_bib57","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1126\/science.1157643","article-title":"A cytosolic iron chaperone that delivers iron to ferritin","volume":"320","author":"Shi","year":"2008","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib58","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1432-1033.1995.tb20581.x","article-title":"Characterisation of two major cellular poly(rC)-binding human proteins, each containing three K-homologous (KH) domains","volume":"230","author":"Leffers","year":"1995","journal-title":"Eur J Biochem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1042\/BJ20140225","article-title":"Chaperone protein involved in transmembrane transport of iron","volume":"462","author":"Yanatori","year":"2014","journal-title":"Biochem J"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100138_bib60","doi-asserted-by":"crossref","first-page":"17303","DOI":"10.1074\/jbc.M116.721936","article-title":"Iron export through the transporter ferroportin 1 Is modulated by the iron chaperone PCBP2","volume":"291","author":"Yanatori","year":"2016","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129685","article-title":"The new role of poly (rC)-binding proteins as iron transport chaperones: proteins that could couple with inter-organelle interactions to safely traffic iron","volume":"1864","author":"Yanatori","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100138_bib62","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/clinchem\/38.9.1883","article-title":"Effect of pH and citrate on binding of iron and gallium by transferrin in serum","volume":"38","author":"McGregor","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.pharmr.2026.100138_bib63","first-page":"1484","article-title":"Role of the acidic receptosome in the uptake and retention of 67Ga by human leukemic HL60 cells","volume":"50","author":"Chitambar","year":"1990","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib64","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1083\/jcb.117.2.301","article-title":"Delivery of ligands from sorting endosomes to late endosomes occurs by maturation of sorting endosomes","volume":"117","author":"Dunn","year":"1992","journal-title":"J Cell Biol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib65","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1007\/s11033-020-05993-4","article-title":"Endosomes, lysosomes, and the role of endosomal and lysosomal biogenesis in cancer development","volume":"47","author":"Jeger","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.pharmr.2026.100138_bib66","first-page":"2063","article-title":"The isolation and characterization of gallium-binding granules from soft tissue tumors","volume":"33","author":"Brown","year":"1973","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib67","first-page":"941","article-title":"Gallium-67 localization in lysosomal-like granules of leukemic and nonleukemic murine tissues","volume":"46","author":"Swartzendruber","year":"1971","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmr.2026.100138_bib68","first-page":"1154","article-title":"Uptake of 67Ga in regenerating rat liver and its relationship to lysosomal enzyme activity","volume":"35","author":"Hammersley","year":"1975","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib69","first-page":"72","article-title":"Isolation of the 67gallium accumulating fraction in normal rat liver","volume":"13","author":"Aulbert","year":"1974","journal-title":"Nucl Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib70","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00304881","article-title":"The role of lysosomal enzyme activity in the localization of 67gallium citrate","volume":"4","author":"Hammersley","year":"1979","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1768-322X.1984.tb00282.x","article-title":"Role of lysosomes in gallium concentration by mammalian tissues","volume":"51","author":"Berry","year":"1984","journal-title":"Biol Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib72","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/exnr.1998.6885","article-title":"Mechanisms of uptake of gallium by human neuroblastoma cells and effects of gallium and aluminum on cell growth, lysosomal protease, and choline acetyl transferase activity","volume":"153","author":"Dobson","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmr.2026.100138_bib73","first-page":"608","article-title":"In vitro transfer of Ga-67 from transferrin to ferritin","volume":"24","author":"Weiner","year":"1983","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00448546","article-title":"The role of ferritin in the intracellular distribution of gallium 67","volume":"9","author":"Nakamura","year":"1984","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib75","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.105.099044","article-title":"Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates","volume":"317","author":"Davies","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2026.100138_bib76","first-page":"937","article-title":"The incorporation of Ga-67 into the ferritin fraction of rabbit hepatocytes in vivo","volume":"18","author":"Hegge","year":"1977","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/abio.1997.2126","article-title":"Fluorescence analysis of the labile iron pool of mammalian cells","volume":"248","author":"Epsztejn","year":"1997","journal-title":"Anal Biochem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100138_bib78","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood-2005-02-0460","article-title":"Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells","volume":"106","author":"Glickstein","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2026.100138_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2020.213645","article-title":"Fluorescent probes for iron, heme, and related enzymes","volume":"429","author":"Sun","year":"2021","journal-title":"Coord Chem Rev"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100138_bib80","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.274.19.13375","article-title":"Calcein as a fluorescent probe for ferric iron","volume":"274","author":"Thomas","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100138_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotochem.2023.114656","article-title":"Comparison of two pyrazole derived \u201cturn on\u201d fluorescent probes for the recognition of Ga3+","volume":"440","author":"Wei","year":"2023","journal-title":"J Photochem Photobiol A"},{"key":"10.1016\/j.pharmr.2026.100138_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.dyepig.2023.111621","article-title":"A new fluorescent vitamin B6-based probe for selective and sensitive detection Ga3+ ions in the environment and living cells","volume":"219","author":"Zavalishin","year":"2023","journal-title":"Dyes Pigments"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100138_bib83","doi-asserted-by":"crossref","first-page":"14762","DOI":"10.1016\/S0021-9258(17)42668-8","article-title":"Complete inhibition of transferrin recycling by monensin in K562 cells","volume":"259","author":"Stein","year":"1984","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib84","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0021-9258(18)49946-2","article-title":"Regulation of the transferrin-independent iron transport system in cultured cells","volume":"266","author":"Kaplan","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100138_bib85","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1016\/S0021-9258(18)52906-9","article-title":"Characterization of transferrin-independent iron transport in K562 cells","volume":"268","author":"Inman","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100138_bib86","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.V80.2.505.bloodjournal802505","article-title":"Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells","volume":"80","author":"Chitambar","year":"1992","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib87","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1074\/jbc.272.5.2599","article-title":"Polyvalent cationic metals induce the rate of transferrin-independent iron acquisition by HL-60 cells","volume":"272","author":"Olakanmi","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100138_bib88","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood.V91.12.4686","article-title":"Transferrin receptor-dependent and -independent iron transport in gallium-resistant human lymphoid leukemic cells","volume":"91","author":"Chitambar","year":"1998","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib89","first-page":"2135","article-title":"Distribution of gallium-67 in normal and hypotransferrinemic tumor-bearing mice","volume":"34","author":"Sohn","year":"1993","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF03164602","article-title":"67Ga in transferrin-unbound form is taken up by inflamed liver of mouse treated with CCl4","volume":"4","author":"Ohkubo","year":"1990","journal-title":"Ann Nucl Med"},{"issue":"39","key":"10.1016\/j.pharmr.2026.100138_bib91","doi-asserted-by":"crossref","first-page":"11850","DOI":"10.1021\/bi00205a022","article-title":"Extracellular ferrireductase activity of K562 cells is coupled to transferrin-independent iron transport","volume":"33","author":"Inman","year":"1994","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib92","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1083\/jcb.139.4.895","article-title":"Functional expression cloning and characterization of SFT, a stimulator of Fe transport","volume":"139","author":"Gutierrez","year":"1997","journal-title":"J Cell Biol"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100138_bib93","doi-asserted-by":"crossref","first-page":"21380","DOI":"10.1074\/jbc.273.33.21380","article-title":"Structural and functional analysis of SFT, a stimulator of Fe Transport","volume":"273","author":"Yu","year":"1998","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100138_bib94","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1073\/pnas.68.7.1623","article-title":"Antitumor activity and toxicity of salts of inorganic Group IIIa metals: aluminum, gallium, indium, and thallium","volume":"68","author":"Hart","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100138_bib95","first-page":"1311","article-title":"Gallium nitrate: the second metal with clinical activity","volume":"70","author":"Foster","year":"1988","journal-title":"Cancer Treat Rep"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100138_bib96","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1021\/ic00260a033","article-title":"Neutral water-soluble post-transition-metal chelate complexes of medical interest: aluminum and gallium tris(3-hydroxy-4-pyronates)","volume":"26","author":"Finnegan","year":"1987","journal-title":"Inorg Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib97","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0278-6915(88)90005-1","article-title":"Tissue distribution of gallium following administration of the gallium-maltol complex in the rat: a model for an aluminium-maltol complex of neurotoxicological interest","volume":"26","author":"Farrar","year":"1988","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1155\/MBD.2000.33","article-title":"Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability","volume":"7","author":"Bernstein","year":"2000","journal-title":"Met-Based Drugs"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib99","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S0885715600014524","article-title":"Powder X-ray crystallography of gallium 3-hydroxy-4-pyronates","volume":"10","author":"Bernstein","year":"1995","journal-title":"Powder Diffr"},{"issue":"7_Supplement","key":"10.1016\/j.pharmr.2026.100138_bib100","first-page":"230","article-title":"Gallium maltolate treatment results in transferrin-bound gallium in patient serum","volume":"45","author":"Allamneni","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib101","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2710.1991.tb00292.x","article-title":"Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test","volume":"16","author":"Kelsey","year":"1991","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib102","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.3390\/ijms22115546","article-title":"New Era in the treatment of iron deficiency anaemia using trimaltol iron and other lipophilic iron chelator complexes: historical perspectives of discovery and future applications","volume":"22","author":"Kontoghiorghes","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2\u20133","key":"10.1016\/j.pharmr.2026.100138_bib103","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtemb.2012.03.015","article-title":"Intestinal iron absorption","volume":"26","author":"Fuqua","year":"2012","journal-title":"J Trace Elem Med Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib104","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cmet.2015.09.006","article-title":"Ironing out ferroportin","volume":"22","author":"Drakesmith","year":"2015","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148671","article-title":"Ironing out mechanisms of iron homeostasis and disorders of iron deficiency","volume":"131","author":"Koleini","year":"2021","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100138_bib106","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0277-5379(82)90212-7","article-title":"Tumor cell toxicity of stable gallium nitrate: enhancement by transferrin and protection by iron","volume":"18","author":"Rasey","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib107","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/0008-5472.CAN-10-3614","article-title":"Ironing out cancer","volume":"71","author":"Torti","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib108","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/nyas.13008","article-title":"Iron and cancer: recent insights","volume":"1368","author":"Manz","year":"2016","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib109","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/1097-0142(197911)44:5<1722::AID-CNCR2820440528>3.0.CO;2-C","article-title":"Clinical toxicologic and pharmacologic studies of gallium nitrate","volume":"44","author":"Krakoff","year":"1979","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib110","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1172\/JCI111087","article-title":"Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide","volume":"72","author":"Chitambar","year":"1983","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib111","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI112746","article-title":"Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium","volume":"78","author":"Chitambar","year":"1986","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib112","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1172\/JCI112381","article-title":"Transferrin synthesis by inducer T lymphocytes","volume":"77","author":"Lum","year":"1986","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib113","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1073\/pnas.80.11.3494","article-title":"Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2","volume":"80","author":"Neckers","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib114","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.143.3.787","article-title":"Transferrin receptor synthesis is an early event in B cell activation","volume":"143","author":"Futran","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmr.2026.100138_bib115","first-page":"1125","article-title":"Modulation of lymphocyte proliferation and immunoglobulin production by transferrin-gallium","volume":"49","author":"Chitambar","year":"1989","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib116","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood.V72.6.1930.1930","article-title":"Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea [see comments]","volume":"72","author":"Chitambar","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2026.100138_bib117","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000163609","article-title":"Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium","volume":"59","author":"Chitambar","year":"2008","journal-title":"Pathobiology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib118","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood.V69.1.144.144","article-title":"Inhibition of hemoglobin production by transferrin-gallium","volume":"69","author":"Chitambar","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2026.100138_bib119","first-page":"418","article-title":"Transferrin receptor-mediated suppression of in vitro hematopoiesis by transferrin-gallium","volume":"17","author":"Chitambar","year":"1989","journal-title":"Exp Hematol"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100138_bib120","doi-asserted-by":"crossref","first-page":"12151","DOI":"10.1074\/jbc.272.18.12151","article-title":"Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium\/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production","volume":"272","author":"Chitambar","year":"1997","journal-title":"J Biol Chem"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100138_bib121","doi-asserted-by":"crossref","first-page":"18148","DOI":"10.1016\/S0021-9258(19)37165-0","article-title":"Ferritin: a cytoprotective antioxidant strategem of endothelium","volume":"267","author":"Balla","year":"1992","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib122","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/bj3570241","article-title":"Ferritin and the response to oxidative stress","volume":"357","author":"Orino","year":"2001","journal-title":"Biochem J"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100138_bib123","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1128\/MCB.20.16.5818-5827.2000","article-title":"Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress","volume":"20","author":"Tsuji","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100138_bib124","doi-asserted-by":"crossref","first-page":"19738","DOI":"10.1074\/jbc.M100245200","article-title":"Modulation of cellular iron metabolism by hydrogen peroxide","volume":"276","author":"Caltagirone","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.bi.48.070179.001025","article-title":"Reduction of ribonucleotides","volume":"48","author":"Thelander","year":"1979","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.pharmr.2026.100138_bib126","series-title":"Inhibitors of Ribonucleoside Diphosphate Reductase Activity","first-page":"127","article-title":"The role of ribonucleotide reductase in regulation of the deoxyribonucleoside triphosphate pool composition: studies with a kinetic model","author":"Jackson","year":"1989"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib127","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1146\/annurev.biochem.75.103004.142443","article-title":"Ribonucleotide reductases","volume":"75","author":"Nordlund","year":"2006","journal-title":"Annu Rev Biochem"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100138_bib128","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1016\/S0021-9258(17)39337-7","article-title":"Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits","volume":"260","author":"Engstr\u00f6m","year":"1985","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib129","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0014-4827(88)90165-6","article-title":"The structural gene for the M1 subunit of ribonucleotide reductase maps to chromosome 11, band p15, in human and to chromosome 7 in mouse","volume":"174","author":"Brissenden","year":"1988","journal-title":"Exp Cell Res"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100138_bib130","doi-asserted-by":"crossref","first-page":"11695","DOI":"10.1016\/S0021-9258(20)71265-2","article-title":"Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis","volume":"259","author":"Eriksson","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100138_bib131","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0065-2571(81)90013-3","article-title":"Specific inhibition of the subunits of ribonucleotide reductase as a new approach to combination chemotherapy","volume":"19","author":"Cory","year":"1981","journal-title":"Adv Enzyme Regul"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib132","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.gendis.2022.11.022","article-title":"Ribonucleotide reductase M2 (RRM2): regulation, function and targeting strategy in human cancer","volume":"11","author":"Zuo","year":"2024","journal-title":"Genes Dis"},{"key":"10.1016\/j.pharmr.2026.100138_bib133","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fonc.2011.00056","article-title":"Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization","volume":"1","author":"Chapman","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.pharmr.2026.100138_bib134","first-page":"139","article-title":"The tyrosyl free radical in ribonucleotide reductase","volume":"64","author":"Gr\u00e4slund","year":"1985","journal-title":"Environ Health Perspect"},{"issue":"35","key":"10.1016\/j.pharmr.2026.100138_bib135","doi-asserted-by":"crossref","first-page":"26200","DOI":"10.1016\/S0021-9258(19)74300-2","article-title":"Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators","volume":"268","author":"Nyholm","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100138_bib136","first-page":"3014","article-title":"Effect of gallium on DNA synthesis by human T-cell lymphoblasts","volume":"48","author":"Hedley","year":"1988","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib137","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/0006-2952(92)90686-D","article-title":"Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase","volume":"44","author":"Narasimhan","year":"1992","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib138","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1021\/bi00432a039","article-title":"Reduced forms of the iron-containing small subunit of ribonucleotide reductase from Escherichia coli","volume":"28","author":"Sahlin","year":"1989","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib139","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1158\/1535-7163.MCT-17-1009","article-title":"Gallium maltolate disrupts tumor iron metabolism and retards the growth of glioblastoma by inhibiting mitochondrial function and ribonucleotide reductase","volume":"17","author":"Chitambar","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmr.2026.100138_bib140","first-page":"6199","article-title":"Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells","volume":"51","author":"Chitambar","year":"1991","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib141","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1021\/ja00523a004","article-title":"Nucleoside complexing. A Raman and 13C NMR spectroscopic study of the binding of hard and soft metal species","volume":"102","author":"Marzilli","year":"1980","journal-title":"J Am Chem Soc"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100138_bib142","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1021\/acs.jpcb.9b03145","article-title":"Novel insights into gallium\u2019s mechanism of therapeutic action: a DFT\/PCM study of the interaction between Ga 3+ and ribonucleotide reductase substrates","volume":"123","author":"Kircheva","year":"2019","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.pharmr.2026.100138_bib143","first-page":"428","article-title":"Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells","volume":"23","author":"Haq","year":"1995","journal-title":"Exp Hematol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib144","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1158\/1535-7163.MCT-06-0285","article-title":"Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition","volume":"5","author":"Chitambar","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.1995.tb08927.x","article-title":"Iron chelators induce apoptosis in proliferating cells","volume":"89","author":"Hileti","year":"1995","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib146","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10495-005-0812-8","article-title":"Iron deprivation induces apoptosis via mitochondrial changes related to Bax translocation","volume":"10","author":"Koc","year":"2005","journal-title":"Apoptosis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib147","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.freeradbiomed.2008.05.031","article-title":"Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells","volume":"45","author":"Yang","year":"2008","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib148","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1124\/jpet.107.126342","article-title":"Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate","volume":"322","author":"Chitambar","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib149","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1158\/1535-7163.MCT-06-0557","article-title":"Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate","volume":"6","author":"Yang","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"3 Pt 1","key":"10.1016\/j.pharmr.2026.100138_bib150","doi-asserted-by":"crossref","first-page":"L443","DOI":"10.1152\/ajplung.1999.276.3.L443","article-title":"Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells","volume":"276","author":"Suttner","year":"1999","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100138_bib151","doi-asserted-by":"crossref","first-page":"14937","DOI":"10.1074\/jbc.272.23.14937","article-title":"Heme oxygenase-mediated resistance to oxygen toxicity in hamster fibroblasts","volume":"272","author":"Dennery","year":"1997","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib152","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.3390\/ijms14036044","article-title":"The role of metallothionein in oxidative stress","volume":"14","author":"Ruttkay-Nedecky","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib153","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0968-0004(00)01589-9","article-title":"Maturation of cellular Fe-S proteins: an essential function of mitochondria","volume":"25","author":"Lill","year":"2000","journal-title":"Trends Biochem Sci"},{"issue":"7257","key":"10.1016\/j.pharmr.2026.100138_bib154","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nature08301","article-title":"Function and biogenesis of iron-sulphur proteins","volume":"460","author":"Lill","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib155","first-page":"304","article-title":"Gallium deregulates mitochondrial aconitase gene in human prostate carcinoma cells","volume":"1","author":"Tsui","year":"2007","journal-title":"Andrology Update"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib156","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/jid.2014.476","article-title":"Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice","volume":"135","author":"Wu","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib157","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/0885066616658449","article-title":"Measurement of mitochondrial respiration and motility in acute care: sepsis, trauma, and poisoning","volume":"32","author":"Jang","year":"2017","journal-title":"J Intensive Care Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib158","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1021\/ja961330f","article-title":"Preparation and characterization of [2Ga-2S] anabaena 7120 ferredoxin, the first gallium\u2212sulfur cluster-containing protein","volume":"119","author":"Vo","year":"1997","journal-title":"J Am Chem Soc"},{"issue":"36","key":"10.1016\/j.pharmr.2026.100138_bib159","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1021\/bi100712g","article-title":"Structural and functional characterization of the ga-substituted ferredoxin from Synechocystis sp. PCC6803, a mimic of the native protein","volume":"49","author":"Xu","year":"2010","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib160","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1107\/S090744490302794X","article-title":"Metal-substituted derivatives of the rubredoxin from Clostridium pasteurianum","volume":"60","author":"Maher","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100138_bib161","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.18632\/oncotarget.27567","article-title":"The cytotoxicity of gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex","volume":"11","author":"Alhajala","year":"2020","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib162","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-biochem-070511-103700","article-title":"Mitochondrial complex I","volume":"82","author":"Hirst","year":"2013","journal-title":"Annu Rev Biochem"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100138_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251810047","article-title":"Gallium uncouples iron metabolism to enhance glioblastoma radiosensitivity","volume":"25","author":"Owusu","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1306.001","article-title":"Iron metabolism and the IRE\/IRP regulatory system: an update","volume":"1012","author":"Pantopoulos","year":"2004","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112404","article-title":"Gallium disrupts endoplasmic reticulum iron metabolism to induce lipid metabolic reprogramming in glioblastoma cells","volume":"28","author":"Petronek","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.pharmr.2026.100138_bib166","first-page":"385","article-title":"DNA polymerases of Walker 256 carcinosarcoma","volume":"34","author":"Waalkes","year":"1974","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib167","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00001813-199906000-00008","article-title":"Microtubule-disrupting effects of gallium chloride in vitro","volume":"10","author":"Perchellet","year":"1999","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmr.2026.100138_bib168","first-page":"1862","article-title":"Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate","volume":"53","author":"Berggren","year":"1993","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib169","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF01757356","article-title":"The effect of free gallium and gallium in liposomes on cytokine and nitric oxide secretion from macrophage-like cells in vitro","volume":"44","author":"Makkonen","year":"1995","journal-title":"Inflamm Res"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100138_bib170","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.3390\/cells11223698","article-title":"The role of IL-6 in cancer cell invasiveness and metastasis\u2014overview and therapeutic opportunities","volume":"11","author":"Ra\u0161kov\u00e1","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib171","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3390\/cancers13081946","article-title":"The role of macrophages in cancer development and therapy","volume":"13","author":"Cendrowicz","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib172","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2026.100138_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104119","article-title":"The roles of tumor-associated macrophages in tumor angiogenesis and metastasis","volume":"353","author":"Fu","year":"2020","journal-title":"Cell Immunol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib174","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/ar.24188","article-title":"Metalloproteinases and their roles in human cancer","volume":"303","author":"Roy","year":"2020","journal-title":"Anat Rec"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0300-9084(00)00384-9","article-title":"The effect of gallium nitrate on synoviocyte MMP activity","volume":"82","author":"Panagakos","year":"2000","journal-title":"Biochimie"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib176","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1039\/C7MT00049A","article-title":"A new gallium complex inhibits tumor cell invasion and matrix metalloproteinase MMP-14 expression and activity","volume":"9","author":"Mohsen","year":"2017","journal-title":"Metallomics"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib177","first-page":"687","article-title":"Preclinical toxicology and tissue gallium distribution of a novel antitumour gallium compound: tris (8-quinolinolato) gallium (III)","volume":"16","author":"Collery","year":"1996","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib178","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jinorgbio.2006.07.003","article-title":"Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins","volume":"100","author":"Rudnev","year":"2006","journal-title":"J Inorg Biochem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib179","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1039\/b902861g","article-title":"Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects","volume":"1","author":"Timerbaev","year":"2009","journal-title":"Metallomics"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib180","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CMR.0b013e32832b272d","article-title":"The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines","volume":"19","author":"Valiahdi","year":"2009","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib181","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13046-017-0527-z","article-title":"Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells\u2014synergism with autophagy inhibition","volume":"36","author":"Kubista","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100138_bib182","series-title":"Metal Ions in Biology and Medicine","first-page":"521","article-title":"Preclinical and early clinical development of the antitumor gallium complex KP46 (FFC11)","author":"Collery","year":"2006"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib183","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1535-7163.MCT-14-0087","article-title":"Calpain-mediated integrin deregulation as a novel mode of action for the anticancer gallium compound KP46","volume":"13","author":"Jungwirth","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib184","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1476-5381.2011.01780.x","article-title":"Gallium compound GaQ 3 -induced Ca 2+ signalling triggers p53-dependent and -independent apoptosis in cancer cells","volume":"166","author":"Gogna","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100138_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113974","article-title":"The gallium complex KP46 sensitizes resistant leukemia cells and overcomes Bcl-2-induced multidrug resistance in lymphoma cells via upregulation of Harakiri and downregulation of XIAP in vitro","volume":"156","author":"Wilke","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2026.100138_bib186","series-title":"Metal Ions in Biology and Medicine","first-page":"110","article-title":"Synergistic antiproliferative effects of tris(8-quinolinolato)gallium(III) (KP46) in combination with platinum drugs in ovarian and colon carcinoma cells","author":"Jakupec","year":"2008"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib187","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib188","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib189","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib191","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13402-023-00804-x","article-title":"Gallium maltolate shows synergism with cisplatin and activates nucleolar stress and ferroptosis in human breast carcinoma cells","volume":"46","author":"Chen","year":"2023","journal-title":"Cell Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib192","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1152\/ajpendo.90897.2008","article-title":"Biochemical and physiological function of stearoyl-CoA desaturase","volume":"297","author":"Paton","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100138_bib193","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-19-0369","article-title":"Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death","volume":"79","author":"Tesfay","year":"2019","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib194","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.trecan.2023.03.003","article-title":"Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis","volume":"9","author":"Sen","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib195","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3095749","article-title":"Gallium(III) complex with Cloxyquin ligands induces ferroptosis in cancer cells and is a potent agent against both differentiated and tumorigenic cancer stem rhabdomyosarcoma cells","volume":"2022","author":"Hreusova","year":"2022","journal-title":"Bioinorg Chem Appl"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib196","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1021\/acs.jmedchem.2c01374","article-title":"Multitarget-directed gallium(III) Tris(acyl-pyrazolonate) complexes induce ferroptosis in cancer cells via dysregulation of cell redox homeostasis and inhibition of the mevalonate pathway","volume":"66","author":"Romani","year":"2023","journal-title":"J Med Chem"},{"issue":"36","key":"10.1016\/j.pharmr.2026.100138_bib197","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202307838","article-title":"Gallium triggers ferroptosis through a synergistic mechanism","volume":"62","author":"Peng","year":"2023","journal-title":"Angew Chem Int Ed"},{"issue":"7498","key":"10.1016\/j.pharmr.2026.100138_bib198","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13148","article-title":"Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy","volume":"509","author":"Mancias","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100138_bib199","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fnins.2019.00238","article-title":"NCOA4-mediated ferritinophagy: a potential link to neurodegeneration","volume":"13","author":"Quiles del Rey","year":"2019","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib200","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41420-023-01753-y","article-title":"Ferritinophagy: research advance and clinical significance in cancers","volume":"9","author":"Wang","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.pharmr.2026.100138_bib201","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib202","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0304-3835(98)00104-9","article-title":"Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells","volume":"129","author":"Myette","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmr.2026.100138_bib203","first-page":"6466","article-title":"Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells","volume":"50","author":"Lundberg","year":"1990","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib204","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/jir.1986.6.717","article-title":"Modification of ribonucleotide and deoxyribonucleotide metabolism in interferon-treated human B-Lymphoblastoid cells","volume":"6","author":"Barankiewicz","year":"1986","journal-title":"J Interferon Res"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib205","first-page":"3224","article-title":"Synergistic inhibition of T-lymphoblastic leukemic CCRF-CEM cell growth by gallium and recombinant human alpha-interferon through action on cellular iron uptake","volume":"54","author":"Chitambar","year":"1994","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100138_bib206","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2010.02.034","article-title":"A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells","volume":"34","author":"Chitambar","year":"2010","journal-title":"Leuk Res"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100138_bib207","doi-asserted-by":"crossref","first-page":"9258","DOI":"10.1158\/0008-5472.CAN-07-1813","article-title":"Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti-prostate tumor effects","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib208","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123721","article-title":"Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response","volume":"10","author":"Sesen","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib209","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","article-title":"Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria","volume":"462","author":"Bridges","year":"2014","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmr.2026.100138_bib210","unstructured":"Hata Y, Sandler A, Loehrer P.J, et al. Synergism of Taxol and gallium nitrate in human breast carcinoma cells: schedule dependency. Oncol Res. 1994;6(1):19-24."},{"issue":"18","key":"10.1016\/j.pharmr.2026.100138_bib211","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol Biol Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib212","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/his.13847","article-title":"Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma","volume":"75","author":"Adachi","year":"2019","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib213","first-page":"941","article-title":"Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy","volume":"72","author":"Recht","year":"1990","journal-title":"J Neurol Surg"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib214","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0887-8994(91)90065-S","article-title":"Alteration of DNA synthesis in human brain tumor cells by gallium nitrate in vitro","volume":"7","author":"Whelan","year":"1991","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib215","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0887-8994(92)90083-B","article-title":"Antineoplastic effects of gallium nitrate on human medulloblastoma in vivo","volume":"8","author":"Whelan","year":"1992","journal-title":"Pediatr Neurol"},{"issue":"3A","key":"10.1016\/j.pharmr.2026.100138_bib216","first-page":"1739","article-title":"Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma","volume":"26","author":"Chua","year":"2006","journal-title":"Anticancer Res"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100138_bib217","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.1074\/jbc.270.19.11033","article-title":"Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status","volume":"270","author":"Little","year":"1995","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib218","first-page":"12","article-title":"Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines","volume":"55","author":"Xia","year":"1995","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib219","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0887-8994(91)90101-P","article-title":"Differential effects of gallium nitrate on proliferation of brain tumor cells in vitro","volume":"7","author":"Whelan","year":"1991","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib220","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0887-8994(94)90089-2","article-title":"Gallium nitrate delays the progression of microscopic disease in a human medulloblastoma murine model","volume":"11","author":"Whelan","year":"1994","journal-title":"Pediatr Neurol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib221","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1039\/b416256k","article-title":"Metal complexes of maltol and close analogues in medicinal inorganic chemistry","volume":"35","author":"Thompson","year":"2006","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.pharmr.2026.100138_bib222","first-page":"823","article-title":"Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study","volume":"67","author":"Weick","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.pharmr.2026.100138_bib223","first-page":"1221","article-title":"Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a SouthEastern Cancer Study Group trial","volume":"70","author":"Keller","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib224","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/1097-0142(19830601)51:11<1982::AID-CNCR2820511104>3.0.CO;2-L","article-title":"Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion","volume":"51","author":"Warrell","year":"1983","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib225","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.2487.2487","article-title":"Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin\u2019s lymphoma (NHL)","volume":"104","author":"Pro","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib226","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0090-4295(91)80152-W","article-title":"Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study","volume":"38","author":"Crawford","year":"1991","journal-title":"Urology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib227","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/1097-0142(19911215)68:12<2561::AID-CNCR2820681205>3.0.CO;2-G","article-title":"Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors","volume":"68","author":"Seidman","year":"1991","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100138_bib228","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/jnci\/83.21.1582","article-title":"Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate","volume":"83","author":"Seligman","year":"1991","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib229","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib230","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.hoc.2024.05.012","article-title":"Cutaneous T-cell lymphoma","volume":"38","author":"Weiner","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Supplement_4","key":"10.1016\/j.pharmr.2026.100138_bib231","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib232","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib233","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib234","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1020718718550","article-title":"Brain iron uptake and homeostatic mechanisms: an overview","volume":"16","author":"Burdo","year":"2003","journal-title":"Biometals"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib235","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1471-4159.2007.04976.x","article-title":"Iron trafficking inside the brain","volume":"103","author":"Moos","year":"2007","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib236","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccell.2015.09.002","article-title":"Preferential iron trafficking characterizes glioblastoma stem-like cells","volume":"28","author":"Schonberg","year":"2015","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib237","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1039\/c3mt00158j","article-title":"The oxidation states and chemical environments of iron and zinc as potential indicators of brain tumour malignancy grade\u2014preliminary results","volume":"5","author":"Wandzilak","year":"2013","journal-title":"Metallomics"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib238","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/tomography8020065","article-title":"Basal ganglia iron content increases with glioma severity using quantitative susceptibility mapping: a potential biomarker of tumor severity","volume":"8","author":"Reith","year":"2022","journal-title":"Tomography"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib239","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/0008-5472.CAN-10-1375","article-title":"Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents","volume":"71","author":"Liu","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100138_bib240","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1278157","article-title":"Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma","volume":"13","author":"Al-Gizawiy","year":"2024","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2026.100138_bib241","article-title":"Potent radiosensitizing effect of the novel metallocompound, gallium maltolate, for the treatment of glioblastoma in vivo","volume":"1","author":"Al-Gizawiy","year":"2025","journal-title":"Neuro-oncol Pediatr"},{"issue":"suppl 5","key":"10.1016\/j.pharmr.2026.100138_bib242","doi-asserted-by":"crossref","first-page":"v370","DOI":"10.1093\/neuonc\/noaf201.1466","article-title":"EXTH-134. The oral iron mimetic gallium maltolate is neurologically safe in a rat xenograft model of glioblastoma: multimodal assessment","volume":"27","author":"Al-Gizawiy","year":"2025","journal-title":"Neuro-oncology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib243","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr2781","article-title":"Breast cancer metastasis to the bone: mechanisms of bone loss","volume":"12","author":"Chen","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100138_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115783","article-title":"Epidemiology of bone metastases","volume":"158","author":"Ryan","year":"2022","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0093-7754(03)00171-4","article-title":"Treatment of cancer-related hypercalcemia: the role of gallium nitrate","volume":"30","author":"Leyland-Jones","year":"2003","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib246","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nm.1910","article-title":"Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation","volume":"15","author":"Ishii","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2026.100138_bib247","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73539","article-title":"Transferrin receptor 1-mediated iron uptake regulates bone mass in mice via osteoclast mitochondria and cytoskeleton","volume":"11","author":"Das","year":"2022","journal-title":"eLife"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib248","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00170-2","article-title":"The effects of gallium nitrate on bone resorption","volume":"30","author":"Bockman","year":"2003","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib249","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jbmr.5650080113","article-title":"Gallium nitrate regulates rat osteoblast expression of osteocalcin protein and mRNA levels","volume":"8","author":"Guidon","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib250","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1476-5381.2010.00665.x","article-title":"Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts","volume":"159","author":"Verron","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib251","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.bcp.2011.12.015","article-title":"Molecular effects of gallium on osteoclastic differentiation of mouse and human monocytes","volume":"83","author":"Verron","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100138_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173613","article-title":"AP-002: a novel inhibitor of osteoclast differentiation and function without disruption of osteogenesis","volume":"889","author":"Wang","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib253","first-page":"1121","article-title":"Toxicity and antitumor activity of gallium nitrate and periodically related metal salts","volume":"47","author":"Hart","year":"1971","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib254","first-page":"131","article-title":"Phase I\u2013II clinical trial of gallium nitrate (NSC-15200)","volume":"3","author":"Samson","year":"1980","journal-title":"Cancer Clin Trials"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib255","first-page":"1449","article-title":"Phase I clinical studies with gallium nitrate","volume":"62","author":"Bedikian","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib256","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/1097-0142(197911)44:5<1728::AID-CNCR2820440529>3.0.CO;2-S","article-title":"Gallium nitrate (NSC-15200) induced toxicity in the rat.A pharmacologic, histopathologic and microanalytical investigation","volume":"44","author":"Newman","year":"1979","journal-title":"Cancer"},{"issue":"Suppl 7","key":"10.1016\/j.pharmr.2026.100138_bib257","article-title":"Phase I study of oral gallium maltolate in patients with refractory malignancies. [abstract] 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","volume":"S48","author":"Srinivas","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmr.2026.100138_bib258","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/187152011796011046","article-title":"Hepatocellular detection by gallium scan and subsequent treatment by gallium maltolate: rationale and case study","volume":"11","author":"Bernstein","year":"2011","journal-title":"Anit-cancer Agents in Medicinal Chemistry"},{"issue":"suppl 5","key":"10.1016\/j.pharmr.2026.100138_bib259","article-title":"Preliminary results of a Phase 1 trial of oral gallium maltolate (GaM) in recurrent glioblastoma","volume":"25","author":"Connelly","year":"2023","journal-title":"Neuro-oncology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib260","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5414\/CPP43590","article-title":"Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors\u2014a Cesar study (Central European Society for Anticancer Drug Research\u2014EWIV)","volume":"43","author":"Hofheinz","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib261","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLM.2005.n.026","article-title":"Activity of gallium nitrate in refractory peripheral T-cell lymphoma","volume":"6","author":"Huang","year":"2005","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.pharmr.2026.100138_bib262","first-page":"47","article-title":"Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate and etoposide","volume":"71","author":"Warrell","year":"1987","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib263","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00000421-199704000-00015","article-title":"Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin\u2019s lymphoma","volume":"20","author":"Chitambar","year":"1997","journal-title":"Am J Clin Oncol"},{"issue":"18_suppl","key":"10.1016\/j.pharmr.2026.100138_bib264","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1200\/jco.2007.25.18_suppl.8079","article-title":"Gallium, rituximab, and dexamethasone for relapsed NHL","volume":"25","author":"Smith","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib265","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1172\/JCI111353","article-title":"Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia","volume":"73","author":"Warrell","year":"1984","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib266","first-page":"595","article-title":"A multicenter trial of low dose gallium nitrate in patients with advanced Paget\u2019s disease of bone","volume":"80","author":"Bockman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2026.100138_bib267","first-page":"21","article-title":"Studies on the mechanism of action of gallium nitrate","volume":"18","author":"Bockman","year":"1991","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib268","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/10428190210321","article-title":"Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate","volume":"43","author":"Niesvizky","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib269","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib270","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.1983.1.11.689","article-title":"High-dose cytosine arabinoside in non-Hodgkin\u2019s lymphoma","volume":"1","author":"Kantarjian","year":"1983","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100138_bib271","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/1097-0142(19811101)48:9<1927::AID-CNCR2820480902>3.0.CO;2-#","article-title":"Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B","volume":"48","author":"Cavalli","year":"1981","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100138_bib272","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-120-9-199405010-00010","article-title":"2-chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies","volume":"120","author":"Saven","year":"1994","journal-title":"Ann Intern Med"},{"issue":"sup2","key":"10.1016\/j.pharmr.2026.100138_bib273","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/10428199409052691","article-title":"Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience","volume":"14","author":"O\u2019Brien","year":"1994","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib274","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jnci\/55.6.1265","article-title":"Adriamycin-a review","volume":"55","author":"Carter","year":"1975","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmr.2026.100138_bib275","first-page":"1231","article-title":"Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin\u2019s lymphomas and other malignancies","volume":"63","author":"Radice","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib276","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma","volume":"10","author":"Redman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmr.2026.100138_bib277","first-page":"439","article-title":"Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment","volume":"62","author":"Rodriguez","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.pharmr.2026.100138_bib278","series-title":"Single agents in cancer chemotherapy. Methotrexate","author":"Livingston","year":"1970"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib279","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib280","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ajh.2830410403","article-title":"Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo","volume":"41","author":"Seligman","year":"1992","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib281","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.1994.12.11.2271","article-title":"Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma","volume":"12","author":"Einhorn","year":"1994","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib282","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<110::AID-CNCR16>3.0.CO;2-7","article-title":"Vinblastine, ifosfamide, and gallium nitrate?an active new regimen in patients with advanced carcinoma of the urothelium","volume":"79","author":"Dreicer","year":"1997","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib283","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.1997.15.6.2449","article-title":"Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib284","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0022-5347(17)57339-5","article-title":"cis-diamminedichloroplatinum II in advanced urothelial cancer","volume":"120","author":"Soloway","year":"1978","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100138_bib285","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1200\/JCO.22.02763","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study","volume":"41","author":"von der Maase","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib286","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib287","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14796694.2025.2482363","article-title":"Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer","volume":"21","author":"Sternschuss","year":"2025","journal-title":"Future Oncol"},{"issue":"7_suppl","key":"10.1016\/j.pharmr.2026.100138_bib288","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1200\/JCO.2026.44.7_suppl.686","article-title":"Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras","volume":"44","author":"Cigliola","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib289","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.1987.5.2.292","article-title":"Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases","volume":"5","author":"Warrell","year":"1987","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib290","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.1993.11.12.2443","article-title":"Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study","volume":"11","author":"Warrell","year":"1993","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib291","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00130404-200601000-00009","article-title":"Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia","volume":"12","author":"Cvitkovic","year":"2006","journal-title":"Cancer J"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib292","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.1991.9.8.1467","article-title":"A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia","volume":"9","author":"Warrell","year":"1991","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib293","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/0003-4819-113-11-847","article-title":"Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis","volume":"113","author":"Warrell","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmr.2026.100138_bib294","unstructured":"Genta Company. https:\/\/en.wikipedia.org\/wiki\/Genta_(company). Accessed December 30, 2019."},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib295","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1074-5521(02)00250-8","article-title":"Genta incorporated","volume":"9","author":"McCarthy","year":"2002","journal-title":"Chem Biol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100138_bib296","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/1097-0142(19801101)46:9<2009::AID-CNCR2820460919>3.0.CO;2-A","article-title":"Pharmacokinetics of gallium nitrate in man","volume":"46","author":"Kelsen","year":"1980","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100138_bib297","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2026.100138_bib298","first-page":"4468","article-title":"Development of drug resistance to gallium nitrate through modulation of cellular iron uptake","volume":"50","author":"Chitambar","year":"1990","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100138_bib299","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/antiox13070825","article-title":"Metallothionein: a comprehensive review of its classification, structure, biological functions, and applications","volume":"13","author":"Yang","year":"2024","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib300","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.leukres.2005.08.016","article-title":"Four human T(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma","volume":"30","author":"Tucker","year":"2006","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib301","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0006-2952(99)00301-9","article-title":"Regulation of metallothionein gene expression by oxidative stress and metal ions","volume":"59","author":"Andrews","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib302","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biom12030360","article-title":"Metallothionein and cadmium toxicology\u2014historical review and commentary","volume":"12","author":"Nordberg","year":"2022","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib303","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/jn\/130.5.1085","article-title":"Metallothionein expression in animals: a physiological perspective on function","volume":"130","author":"Davis","year":"2000","journal-title":"J Nutr"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib304","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/emph\/eoz025","article-title":"Experimental evolution of gallium resistance in Escherichia coli","volume":"2019","author":"Graves","year":"2019","journal-title":"Evol Med Public Health"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib305","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41598-025-85772-y","article-title":"Escherichia coli growing under antimicrobial gallium nitrate stress reveals new processes of tolerance and toxicity","volume":"15","author":"Salazar-Alem\u00e1n","year":"2025","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2026.100138_bib306","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0165-5728(92)90186-O","article-title":"Suppression of experimental autoimmune encephalomyelitis by gallium nitrate","volume":"39","author":"Whitacre","year":"1992","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib307","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00007890-199603150-00019","article-title":"Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody","volume":"61","author":"Orosz","year":"1996","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib308","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood.V88.8.3056.bloodjournal8883056","article-title":"Modulation of in vitro and in vivo T-cell responses by transferrin-gallium and gallium nitrate","volume":"88","author":"Drobyski","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib309","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/PL00005085","article-title":"Gallium nitrate suppresses lupus in MRL\/lpr mice","volume":"356","author":"Apseloff","year":"1997","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100138_bib310","first-page":"255","article-title":"Gallium prevents adjuvant arthritis in rats and interferes with macrophage\/T-cell function in the immune response","volume":"50","author":"Matkovic","year":"1991","journal-title":"Curr Ther Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib311","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/jid.2011.89","article-title":"Upregulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin","volume":"131","author":"Wu","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib312","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41577-025-01193-y","article-title":"Iron and the immune system","volume":"25","author":"Frost","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmr.2026.100138_bib313","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.816282","article-title":"Iron metabolism and immune regulation","volume":"13","author":"Ni","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib314","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1073\/pnas.66.4.1244","article-title":"Iron: its intracellular localization and possible role in cell division","volume":"66","author":"Robbins","year":"1970","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib315","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2141.1976.tb03570.x","article-title":"Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells","volume":"33","author":"Hoffbrand","year":"1976","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100138_bib316","first-page":"1749","article-title":"Antineuroblastoma activity of desferoxamine in human cell lines","volume":"47","author":"Blatt","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100138_bib317","first-page":"2925","article-title":"Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines","volume":"49","author":"Blatt","year":"1989","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100138_bib318","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1158\/1078-0432.CCR-06-1954","article-title":"Chelators at the cancer coalface: desferrioxamine to Triapine and beyond","volume":"12","author":"Yu","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100138_bib319","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2004-05-1866","article-title":"Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation","volume":"104","author":"Le","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib320","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.freeradbiomed.2005.03.029","article-title":"Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin","volume":"39","author":"Hoke","year":"2005","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib321","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1124\/mol.112.081893","article-title":"The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action","volume":"83","author":"Lui","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib322","first-page":"5370","article-title":"The iron chelator Dp44mT suppresses osteosarcoma\u2019s proliferation, invasion and migration: in vitro and in vivo","volume":"8","author":"Li","year":"2016","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib323","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1476-5381.2011.01526.x","article-title":"Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy","volume":"165","author":"Yu","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100138_bib324","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bbagen.2008.04.003","article-title":"Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents","volume":"1790","author":"Richardson","year":"2009","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib325","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bbamcr.2016.01.026","article-title":"Redox cycling metals: pedaling their roles in metabolism and their use in the development of novel therapeutics","volume":"1863","author":"Kalinowski","year":"2016","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"4\u20135","key":"10.1016\/j.pharmr.2026.100138_bib326","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10534-020-00243-3","article-title":"Iron chelators in cancer therapy","volume":"33","author":"Ibrahim","year":"2020","journal-title":"Biometals"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib327","doi-asserted-by":"crossref","first-page":"106","DOI":"10.18632\/oncotarget.27866","article-title":"Reversing oncogenic transformation with iron chelation","volume":"12","author":"Abdelaal","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmr.2026.100138_bib328","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/4911205","article-title":"Iron chelators in treatment of iron overload","volume":"2022","author":"Entezari","year":"2022","journal-title":"J Toxicol"},{"key":"10.1016\/j.pharmr.2026.100138_bib329","first-page":"4929","article-title":"Effects of a single course of deferoxamine in neuroblastoma patients","volume":"50","author":"Donfrancesco","year":"1990","journal-title":"Cancer Res"},{"issue":"5B","key":"10.1016\/j.pharmr.2026.100138_bib330","first-page":"2109","article-title":"Deferoxamine in children with recurrent neuroblastoma","volume":"14","author":"Blatt","year":"1994","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib331","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMc1105726","article-title":"Deferoxamine for advanced hepatocellular carcinoma","volume":"365","author":"Yamasaki","year":"2011","journal-title":"N Engl J Med"},{"issue":"5837","key":"10.1016\/j.pharmr.2026.100138_bib332","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/294171a0","article-title":"Anti-transferrin receptor monoclonal antibody and toxin\u2013antibody conjugates affect growth of human tumour cells","volume":"294","author":"Trowbridge","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100138_bib333","first-page":"747","article-title":"Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia","volume":"47","author":"Sauvage","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100138_bib334","first-page":"6295","article-title":"Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects","volume":"50","author":"White","year":"1990","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib335","first-page":"1259","article-title":"Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42\/6","volume":"1","author":"Brooks","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib336","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.273","article-title":"Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications","volume":"50","author":"Vela","year":"2018","journal-title":"Exp Mol Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib337","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1158\/0008-5472.CAN-14-2465","article-title":"Hepcidin regulation in prostate and its disruption in prostate cancer","volume":"75","author":"Tesfay","year":"2015","journal-title":"Cancer Res"},{"issue":"43","key":"10.1016\/j.pharmr.2026.100138_bib338","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001127","article-title":"Ferroportin and iron regulation in breast cancer progression and prognosis","volume":"2","author":"Pinnix","year":"2010","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100138_bib339","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood-2012-09-456756","article-title":"The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys","volume":"121","author":"Schwoebel","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib340","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Vadhan-Raj","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100138_bib341","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100138_bib342","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107877","article-title":"Effect of hepcidin antagonists on anemia during inflammatory disorders","volume":"226","author":"Sagar","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100138_bib343","first-page":"3574","article-title":"Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase","volume":"7","author":"Green","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib344","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100087","article-title":"Metal-based antibody, nanobody, and peptide conjugates: potential for breast cancer therapy","volume":"77","author":"Kaya","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib345","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4155\/fmc.12.69","article-title":"Gallium-containing anticancer compounds","volume":"4","author":"Chitambar","year":"2012","journal-title":"Future Med Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100138_bib346","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/15533179108020631","article-title":"Synthesis and characterization of potential antitumor and antiviral gallium(III) complexes of \u03b1-(N)-heterocyclic thiosemicarbazones","volume":"21","author":"Kratz","year":"1991","journal-title":"Synth React Inorg Met-Org Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib347","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0162-0134(02)00419-1","article-title":"Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine 4N-dimethylthiosemicarbazone","volume":"91","author":"Arion","year":"2002","journal-title":"J Inorg Biochem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100138_bib348","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1021\/jm0612618","article-title":"Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase","volume":"50","author":"Kowol","year":"2007","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib349","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.ejmech.2008.11.006","article-title":"Gallium(III) complexes of 2-pyridineformamide thiosemicarbazones: cytotoxic activity against malignant glioblastoma","volume":"44","author":"Mendes","year":"2009","journal-title":"Eur J Med Chem"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100138_bib350","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1021\/ic060106g","article-title":"Synthesis, structure, and anticancer activity of gallium(III) complexes with asymmetric tridentate ligands: growth inhibition and apoptosis induction of cisplatin-resistant neuroblastoma cells","volume":"45","author":"Shakya","year":"2006","journal-title":"Inorg Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100138_bib351","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/168030","article-title":"Synthesis, structure, and antiproliferative activity of three gallium(III) azole complexes","volume":"2010","author":"Zanias","year":"2010","journal-title":"Bioinorg Chem Appl"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib352","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ejmech.2009.10.038","article-title":"Anticancer activity of dinuclear gallium(III) carboxylate complexes","volume":"45","author":"Kalu\u0111erovi\u0107","year":"2010","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100138_bib353","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s10637-010-9449-8","article-title":"Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands","volume":"29","author":"Gallego","year":"2011","journal-title":"Investig New Drugs"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100138_bib354","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.jorganchem.2009.02.027","article-title":"Novel gallium(III) complexes containing phthaloyl derivatives of neutral aminoacids with apoptotic activity in cancer cells","volume":"694","author":"G\u00f3mez-Ruiz","year":"2009","journal-title":"J Organomet Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100138_bib355","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jinorgbio.2010.10.013","article-title":"Organogallium(III) complexes as apoptosis promoting anticancer agents for head and neck squamous cell carcinoma (HNSCC) cell lines","volume":"105","author":"Kalu\u0111erovi\u0107","year":"2011","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.pharmr.2026.100138_bib356","first-page":"1009","article-title":"Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate","volume":"2","author":"Chitambar","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmr.2026.100138_bib357","series-title":"Metal Ions in Biology and Medicine","first-page":"351","article-title":"Antitumor effects of gallium(III) Tris (salicylate)-ethanol on malignant cell lines and tumor bearing Swiss albino mice","author":"Ismail","year":"2006"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100138_bib358","doi-asserted-by":"crossref","first-page":"E2258","DOI":"10.1073\/pnas.1517402113","article-title":"Cellular uptake and anticancer activity of carboxylated gallium corroles","volume":"113","author":"Pribisko","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100138_bib359","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1021\/acsomega.2c07742","article-title":"(8-hydroxyquinoline) gallium(III) complex with high antineoplastic efficacy for treating colon cancer via multiple mechanisms","volume":"8","author":"Zhou","year":"2023","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100138_bib360","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1021\/acsmaterialsau.2c00078","article-title":"Synthesis of antimicrobial gallium nanoparticles using the hot injection method","volume":"3","author":"Limantoro","year":"2023","journal-title":"ACS Mater Au"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100138_bib361","doi-asserted-by":"crossref","DOI":"10.1002\/aoc.70305","article-title":"Gallium oxide nanoparticles with controllable morphologies as effective photocatalytic antimicrobial agents","volume":"39","author":"Wang","year":"2025","journal-title":"Appl Organomet Chem"},{"issue":"38","key":"10.1016\/j.pharmr.2026.100138_bib362","doi-asserted-by":"crossref","first-page":"31122","DOI":"10.1039\/D5RA04216J","article-title":"Antibacterial activity and mechanistic insights of gallium-based nanoparticles: an emerging frontier in metal-based antimicrobials","volume":"15","author":"Ikhazuagbe","year":"2025","journal-title":"RSC Adv"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100138_bib363","doi-asserted-by":"crossref","first-page":"22257","DOI":"10.1021\/acsnano.4c06199","article-title":"A two-pronged nanostrategy of iron metabolism disruption to synergize tumor therapy by triggering the paraptosis-apoptosis hybrid pathway","volume":"18","author":"Lei","year":"2024","journal-title":"ACS Nano"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100138_bib364","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111478","article-title":"Paraptosis\u2014a distinct pathway to cell death","volume":"25","author":"Kunst","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"38","key":"10.1016\/j.pharmr.2026.100138_bib365","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202302551","article-title":"Inhalable capsular polysaccharide-camouflaged gallium-polyphenol nanoparticles enhance lung cancer chemotherapy by depleting local lung microbiota","volume":"35","author":"Han","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.pharmr.2026.100138_bib366","unstructured":"Aridis Pharmaceuticals. https:\/\/www.aridispharma.com\/ar-501\/. Accessed December 30, 2025."},{"issue":"suppl 5","key":"10.1016\/j.pharmr.2026.100138_bib367","article-title":"DDDR-58. RNA-sequencing to investigate antineoplastic mechanisms of gallium maltolate in glioblastoma","volume":"27","author":"Zoss","year":"2025","journal-title":"Neuro-oncology"},{"issue":"38","key":"10.1016\/j.pharmr.2026.100138_bib368","doi-asserted-by":"crossref","first-page":"40896","DOI":"10.18632\/oncotarget.5683","article-title":"IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:34:42Z","timestamp":1785893682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":368,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0031699726000268"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100138","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reharnessing the therapeutic potential of gallium-based compounds in oncology: From the laboratory to the clinic","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100138"}}